Quick Facts

• Primary Use: Used to manage anemias responsive to oral iron therapy.
• Supportive Role: May help address reduced iron and vitamin levels.
• Indications Include: Hypochromic anemia related to pregnancy, blood loss, certain metabolic conditions, and dietary requirements.

Ferralet 90 is indicated for the management of various anemias that demonstrate a positive response to oral iron supplementation. Its core function is to help address lowered levels of iron in the blood, along with deficiencies in Vitamin B12 and Folic Acid.

The medication is prescribed to patients experiencing hypochromic anemia, which is often associated with circumstances such as pregnancy, chronic or acute blood loss, and periods of post-surgical recovery. It may also be utilized when anemia is related to metabolic diseases or insufficient dietary intake of iron and essential vitamins.

Folic acid and Vitamin B12 are integral components of the formulation, supporting the production and maintenance of healthy red blood cells. The intended therapeutic action is to maintain adequate amounts of iron necessary for effective blood production and oxygen transport.

Eligibility and Contraindications

Ferralet 90 is contraindicated and must not be used by patients diagnosed with iron overload disorders, specifically hemochromatosis or hemosiderosis. Absolute exclusion also applies to individuals with hemolytic anemia or known hypersensitivity to any ingredient in the tablet.

Use of the medication is restricted for certain blood conditions. The Folic Acid component is considered improper therapy for pernicious anemia or other megaloblastic anemias caused by a Vitamin B12 deficiency, as this may mask the underlying condition.

Age-Based Rules

Safety and effectiveness have not been established in pediatric patients. A mandatory warning states that this iron-containing product must be kept out of the reach of children under 6 years due to the risk of fatal poisoning from accidental overdose. For elderly patients, treatment initiation requires caution, often beginning at the lower end of the dosing range, particularly in the presence of decreased hepatic, renal, or cardiac function.

Condition-Specific Limitations

The product is indicated for anemias, including those associated with pregnancy, that are responsive to oral iron therapy. Caution is advised for those with aspirin hypersensitivity due to potential sensitivity to the excipient FD&C Yellow No. 5 (tartrazine).

Interactions with other medicines and products

Official regulatory documentation identifies specific interaction patterns for Ferralet 90, which is a combination product containing Iron, Folic Acid, and Cyanocobalamin (Vitamin B12).

Pharmacokinetic and Timing-Based Interactions

The elemental Iron component has documented pharmacokinetic interactions based on chelation, which reduces the systemic absorption of co-administered medicines. The administration of Ferralet 90 must therefore be separated by at least two hours from the oral use of both Tetracyclines and Fluoroquinolones to prevent a significant reduction in antibiotic exposure. Similarly, Antacids reduce the absorption of the Iron component, requiring a minimum separation of administration by two hours.

Pharmacodynamic and Substance Interactions

A critical pharmacodynamic consideration is that the Folic Acid component may mask the hematological symptoms of an underlying Vitamin B12 deficiency (pernicious anemia), allowing progressive neurological damage to continue unchecked. Furthermore, heavy consumption of Alcohol for longer than two weeks is documented to cause malabsorption of the Cyanocobalamin (Vitamin B12) component. The absorption of iron is also reduced when administered with certain foods. For geriatric patients, caution is noted due to the greater frequency of concomitant drug therapy, increasing the overall risk for interactions.

Ferralet 90 modulates system-level iron kinetics via ferrous gluconate and carbonyl iron. In the gastrointestinal lumen, ferrous gluconate dissociates to the ferrous ion ( Fe^2+), which is immediately available for transport across the duodenal enterocyte apical membrane via the divalent metal transporter 1 (DMT1). Carbonyl iron ( Fe^0) is converted to Fe^2+ by gastric acid before uptake. Ascorbic acid (Vitamin C) functions as a chemical enhancer, reducing ferric ion ( Fe^3+) to the more soluble Fe^2+ state, thereby increasing the non-heme iron fraction available for DMT1-mediated absorption. Once within the enterocyte, Fe^2+ is either stored by ferritin or exported into the circulation via ferroportin.

The concurrent presence of folic acid and cyanocobalamin (Vitamin B12) provides essential cofactors for molecular and cellular processes within hematopoietic tissue. Folic acid is reduced to its active form, tetrahydrofolic acid, a necessary cofactor for the biosynthesis of purines and thymidylate, which are integral to DNA synthesis and cellular proliferation. Cyanocobalamin serves as a cofactor for the enzyme methionine synthase, critical for nucleic acid synthesis, and for L-methylmalonyl-CoA mutase, involved in lipid metabolism and myelin synthesis. The collective action of these components increases the systemic supply of iron, folate, and B12, directly supporting the erythropoiesis pathway.

How to Use Ferralet 90: Official Administration Guidelines

Ferralet 90 is a prescription-only medication with a defined set of administration rules. The medication is formulated as a film-coated tablet and is strictly for the oral route of administration.

Standard Dosing and Timing

Feature	Official Instruction
Route of Administration	Oral
Dosing Schedule	One tablet daily
Timing Relative to Meals	Take 2 hours after meals for optimal absorption
Physical Administration	The tablet must not be chewed

---

Use Patterns and Oversight

The standard regimen is once daily, and patients must not exceed the single-tablet daily dose specified in the labeling. The specific timing instruction to take the medicine between meals is provided to support the intended absorption of the active ingredients, which include iron and ascorbic acid.

Duration and Population-Specific Rules

Therapy with Ferralet 90 is not indefinite and requires periodic review by a healthcare provider to determine if continuation or a dose change is indicated. This oversight ensures the duration of use remains clinically appropriate.

For older adults, the official guidance requires that dosing be administered with caution, often starting at the lower end of the dosing range, due to the higher potential for decreased organ function. Furthermore, the safety and effectiveness of Ferralet 90 have not been established in pediatric patients. The protocol requires a physician to determine the specific cause of anemia before treatment begins.

Research Evidence / Overview of Studies for Ferralet 90

The following summary describes the type of research that has been conducted on the active ingredients in Ferralet 90 (Iron, Folic Acid, and Vitamin B12) and what is known—or still uncertain—about the evidence landscape, based only on scientific and regulatory reports. This overview is purely descriptive and does not offer clinical advice.

---

Evidence for Use in Anemia Responsive to Oral Iron Therapy

This section will outline the structure of research and systematic reviews that have examined oral iron compounds and the unique dual-iron component in relation to key hematological biomarkers and patient tolerability.

Research relevant to Iron Deficiency Anemia (IDA) has relied on Systematic Reviews and Meta-analyses that consolidate findings across many studies of oral iron compounds. These studies were generally designed to monitor Hematological Biomarkers—such as Hemoglobin (Hb), Serum Ferritin (which measures iron storage), and Hematocrit—to measure values across defined time intervals.

Specific Randomized Controlled Trials (RCTs) were conducted to compare different forms of iron, including the Carbonyl Iron component, against other common iron salts. Research evaluated the use of oral iron in adults with confirmed IDA. Research examined whether certain forms of iron were associated with different patterns of Gastrointestinal (GI) Tolerability, but findings were mixed across the reviewed studies.

Evidence for Use in Nutritional Deficiency Associated with Pregnancy

This area outlines the structure of research, including trials and observational cohort studies, that evaluated the impact of combined iron, folic acid, and vitamin B12 supplementation on maternal and fetal nutritional status.

The role of Iron and Folic Acid during pregnancy was evaluated through Randomized Controlled Trials and large Observational Studies. Studies monitored changes in maternal Hb and essential vitamin levels, as well as birth outcomes. Systematic Reviews described values measured for maternal hematological status in the context of Iron and Folic Acid supplementation. However, studies that explored the measured values of Hb when supplementary Vitamin B12 was included often report heterogeneous findings in populations not previously diagnosed as deficient.

What is Still Uncertain About Ferralet 90

A key area of uncertainty lies in the comparative evidence available for the specific, unique quintuple-ingredient formulation found in Ferralet 90 (which includes the stool softener, Docusate Sodium). There is a lack of publicly available, large-scale Randomized Controlled Trials that isolate and examine this complete combination against simple iron supplementation. Comparative evidence is lacking.

Furthermore, the product was not studied in pediatric patients, meaning data for certain groups remain insufficient. Long-term effects—specifically those tracking the maintenance of iron and vitamin stores over periods exceeding several months—are not fully established and were not consistently characterized across the available trials.

Key Studies & References Ferralet 90 Product Label (Prescribing Information) – FDA DailyMed

Common questions about Ferralet 90 (FAQ)

---

Q: Why is Ferralet 90 sometimes described as 'chelated' iron?

Official labeling identifies the iron components in Ferralet 90 as ferrous gluconate and carbonyl iron. While the official prescribing information uses these specific chemical names, some information may use the term 'chelated' to generally describe the specialized dual-iron formulation, which is described to have enhanced iron availability and absorption potential.

---

Q: What makes the iron in Ferralet 90 different from regular ferrous sulfate?

Ferralet 90 contains two forms of iron: ferrous gluconate and carbonyl iron, whereas many common iron supplements use ferrous sulfate. Official reports have examined the components in Ferralet 90, suggesting that its components are associated with different absorption and tolerability profiles.

---

Q: Is Ferralet 90 safe for people with kidney problems?

Official guidance indicates that caution is warranted for older patients who may have reduced kidney (renal) function. This suggests that the status of kidney health is a factor considered by the healthcare provider when determining the appropriateness of the medication.

---

Q: Can certain antibiotics be taken at the same time as Ferralet 90?

Official prescribing information notes interactions with antibiotics like Tetracyclines and Fluoroquinolones. The product information mandates that Ferralet 90 and these antibiotics be administered at least two hours apart to ensure proper systemic absorption of both medicines.

---

Q: Can I take Ferralet 90 if I am also taking antacids?

Taking antacids at the same time as Ferralet 90 may reduce the absorption and effectiveness of the iron component. Official guidance indicates that a separation of administration by a minimum of two hours is required to mitigate this effect.

---

Q: How does Ferralet 90's form (chelated iron) help with absorption?

The formulation includes Ascorbic Acid (Vitamin C) alongside the iron components. Official regulatory sources describe the Ascorbic Acid component as a chemical enhancer that supports the conversion of iron into a more available form for uptake by the body.

---

Q: Is Ferralet 90 only used when dietary iron is insufficient?

The official prescribing information indicates the product is used to manage nutritional deficiencies, including anemias that are responsive to iron therapy and are associated with an inadequate dietary intake of iron or other specific nutritional needs.

---

Q: Do official documents mention an increased risk of iron buildup with Ferralet 90?

Official labeling reports that iron overload conditions, such as Hemosiderosis, have been noted in patients who have a genetic predisposition or underlying disorder. For this reason, the medication is strictly contraindicated (not to be used) in patients who already have known iron overload disorders.

---

Q: How quickly does Ferralet 90 start working to raise iron levels?

The official product labeling does not define a single timeframe for the initial onset of action. Instead, official guidance indicates that healthcare providers track the body's response using blood markers (like Hemoglobin and Hematocrit) periodically during therapy to determine progress.

---

Q: Is it normal to feel tired or nauseous when first starting Ferralet 90?

Nausea is listed as a common side effect of oral iron. Official documents state that these gastrointestinal effects are often transient (temporary) and may resolve as the body adjusts to the medication, though a healthcare provider can provide specific guidance.

---

Q: What kind of studies support the use of Ferralet 90 for iron deficiency?

Research is generally structured to monitor hematological biomarkers—such as Hemoglobin and Serum Ferritin—across defined treatment periods. The evidence base includes Systematic Reviews and Randomized Controlled Trials (RCTs) that have examined oral iron compounds.

---

Q: Are there any specific foods or drinks that should be avoided while taking Ferralet 90?

Regulatory sources suggest separating the intake of Ferralet 90 from foods and drinks that can reduce iron absorption, such as dairy products, tea, and coffee. Additionally, official information notes that heavy consumption of alcohol over several weeks can affect the absorption of the Vitamin B12 component.

---

Q: Can taking Ferralet 90 affect the results of blood tests?

Yes, official patient information notes that this medication may interfere with the results of certain laboratory tests. This includes certain tests for occult (hidden) blood in the stools, which official information notes may be interfered with.

---

Q: Is Ferralet 90 gluten-free, dairy-free, or vegetarian-friendly?

The medication has been officially noted as lactose- and gluten-free by the manufacturer. However, specific information regarding other dietary statuses, such as whether the product is dairy-free or vegetarian-friendly, is not uniformly specified across official materials.

---

Q: Is Ferralet 90 used to treat all types of anemia?

Ferralet 90 is indicated for treating anemias that are known to be responsive to oral iron therapy and/or nutritional deficiency. However, it is considered improper therapy for megaloblastic anemias if they are caused primarily by a Vitamin B12 deficiency.

---

Q: How long after starting Ferralet 90 should iron levels be re-checked?

The label does not provide a single, universal re-check interval, as the requirement for follow-up blood work is determined by the healthcare provider. Official guidance requires that the provider assesses periodically whether therapy should be continued or adjusted.

---

Q: Can Ferralet 90 cause allergic reactions?

Allergic-type reactions are documented in official safety information. This includes a sensitization risk from the Folic Acid component and a risk of hypersensitivity reactions, like bronchial asthma, to the inactive ingredient Tartrazine (FD&C Yellow No. 5) in susceptible individuals.

---

Q: Can I take Ferralet 90 if I have a history of ulcers or stomach issues?

Official documents indicate that caution is advised for patients with conditions such as peptic ulcer disease or chronic inflammation of the small intestine. This is due to the potential for the iron component to cause gastrointestinal irritation.

Storage and Disposal Instructions

Ferralet 90 tablets must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F). The product requires protection from moisture and must be kept in a dry place; regulatory guidance advises against storage in a bathroom, as moisture can cause tablet erosion or discoloration.

Handling and Safety

It is mandatory to keep Ferralet 90 out of the reach of children due to the serious risk of fatal poisoning from accidental iron overdose.

Disposal

Unused or expired drugs must be properly discarded. Do not flush the tablets down a toilet or pour them down a drain unless a healthcare professional specifically instructs this. Patients should consult a pharmacist for information on local drug take-back programs for disposal.